APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Clinical Trial Site, Taipei

Clinical Trial Site, New York

Clinical Trial Site, New York

Clinical Trial Site, Taipai

Clinical Trial Site, La Mesa

Clinical Trial Site, Orange

Clinical Trial Site, Denver

Clinical Trial Site, Chicago

Clinical Trial Site, Baltimore

Clinical Trial Site, Boston

Clinical Trial Site, Detroit

Clinical Trial Site, Rochester

Clinical Trial Site, St Louis

Clinical Trial Site, Durham

Clinical Trial Site, Portland

Clinical Trial Site, Buenos Aires

Clinical Trial Site, Westmead

Clinical Trial Site, Ribeirão Preto

Clinical Trial Site, Rio de Janeiro

Clinical Trial Site, São Paulo

Clinical Trial Site, Sofia

Clinical Trial Site, Vancouver

Clinical Trial Site, Nicosia

Clinical Trial Site, Bourdeaux

Clinical Trial Site, Créteil

Clinical Trial Site, Le Kremlin-Bicêtre

Clinical Trial Site, Lille

Clinical Trial Site, Marseille

Clinical Trial Site, Heidelberg

Clinical Trial Site, Münster

Clinical Trial Site, Regensburg

Clinical Trial Site, Pavia

Clinical Trial Site, Rome

Clinical Trial Site, Sicily

Clinical Trial Site, Matsumoto

Clinical Trial Site, Aichi

Clinical Trial Site, Kumamoto

Clinical Trial Site, Kuala Lumpur

Clinical Trial Site, Mexico City

Clinical Trial Site, Groningen

Clinical Trial Site, Lisbon

Clinical Trial Site, Porto

Clinical Trial Site, Barcelona

Clinical Trial Site, Huelva

Clinical Trial Site, Madrid

Clinical Trial Site, Palma de Mallorca

Clinical Trial Site, Umeå

Clinical Trial Site, Istanbul

Clinical Trial Site, Seoul

Clinical Trial Site, Seoul

Clinical Trial Site, London

Clinical Trial Site, London